Interbody Systems: Post Market Clinical Follow-up Study

Stopped early

Conditions studied: Degenerative Disc Disease

In brief

This is a prospective, multi-center study of subjects who will undergo spinal fusion surgery utilizing Stryker Interbody Systems that require post market clinical follow up (PMCF). The primary study hypothesis for each system is that the mean change in NDI (cervical) or ODI (lumbar) from baseline to Month 12 \< -10, that is, the mean improvement exceeds 10 points. In supporting analysis, the same hypotheses will be tested for mean change from baseline to 24 months to demonstrate durability of effectiveness.

Key facts

Study ID

NCT04911257

Run by

K2M, Inc.

People needed

28

Starts

2021-12-07

Expected to finish

2025-03-21

Last updated by the study team

2025-04-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must be planned to undergo spinal fusion surgery utilizing Stryker Interbody Systems for on label indications, which are listed below as inclusion criteria.
• Diagnosed with degenerative disc disease (DDD).
• Please note for Lumbar devices:
• Can also be diagnosed with up to Grade 1 Spondylolisthesis and/or Degenerative Scoliosis. (Chesapeake is not indicated for degenerative scoliosis)
• Cascadia/Mojave/ Sahara/ Monterey AL can also be diagnosed with up to Grade 1 Retrolisthesis.
• Outside of USA, Tritanium is indicated for use in patients with diagnosis of Degenerative Spine Disorders, Spine Revision, Discal and Vertebral Instability; and there is no restriction to Spondylolisthesis Grade.
• Willingness and ability to comply with the requirements of the protocol including follow up requirements.
• Willing and able to sign a study specific informed consent form.
• Skeletally mature (age at least 18 years) and:
• Have had six months of lumbar non operative therapy.
• Have had six weeks of cervical non operative treatment.
• Will undergo interbody fusion at one or two contiguous levels (Chesapeake Cervical Ti is only indicated for use at one level) at:
• L2 L5 for Cascadia lateral hyperlordotic (>22°l).
• L2 S1 for all other lumbar interbody systems.
• C2 T1 for cervical interbody systems.
• Self reports Oswestry Disability Index (ODI) score 30% (raw score of 15/50) for lumbar patients and Neck Disability Index (NDI) score 30% (raw score of 15/50) for cervical patients at pre operative visit.

You may not qualify if…

• Any condition where the implants interfere with anatomical structures or precludes the benefit of spinal surgery.
• For the Tritanium and Monterey AL systems: Any neuromuscular deficit which places an unsafe load on the device during the healing period.
• For the Cascadia, Chesapeake, Mojave and Sahara systems: Metabolic disorders of calcified tissues.
• Biological factors such as smoking or using nonsteroidal anti inflammatory agents/ anticoagulants.
• Immunosuppressive disorders.
• Grossly distorted anatomy. N/A for Tritanium TL, Tritanium Cervical and Monterey AL
• Inadequate tissue coverage or open wounds.
• Infection at index level(s) at the time of surgery.
• Patients with known sensitivity to materials in the device.
• Has a neuromuscular disorder or mental condition (including general neurological conditions, mental illness, senility, and drug/alcohol abuse) which would create an unacceptable risk of fixation failure or complications in postoperative care or willingness to restrict activities or follow medical advice.
• Obesity.
• Other medical or surgical condition which would preclude the potential benefit of spinal implant surgery, such as the presence of tumors, congenital abnormalities, elevation of sedimentation rate unexplained by other diseases, elevation of white blood cell count (WBC) or marked left shift in the WBC differential count.
• For the Tritanium and Monterey AL systems: Any abnormality which affects the normal process of bone remodeling including, but not limited to severe osteoporosis involving the spine, bone absorption, osteopenia, primary or metastatic tumors involving the spine or certain metabolic disorders affecting osteogenesis.
• Please note for Tritanium cervical this also includes rapid joint disease, bone absorption, osteopenia, osteomalacia, and/or osteoporosis.
• For the Tritanium, Monterey AL, Chesapeake and Sahara systems: Prior fusion at the level to be treated (as indicated in the IFU).
• Pregnancy, or if the patient intends to become pregnant during the course of the study.
• Incarcerated at the time of study enrollment.
• Current participation in an investigational study that may impact study outcomes.
• Involved in current or pending litigation regarding a spine surgery.
• Receiving worker's compensation.

Where it is running

• Spine Institute of Louisiana Foundation, Inc. — Shreveport, Louisiana, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• The Spine Clinic of Oklahoma City — Oklahoma City, Oklahoma, United States
• Inova Neurosciences Research — Falls Church, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.